

Finished Formulations Product List



***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

FORMULATIONS

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

OUR VISION
TO REACH 1.5 BILLION
PEOPLE ACROSS THE
GLOBE

PRODUCT NAME*

DOSAGE FORM

A

ABIRATERONE ACETATE

Tablets

ACALABRUTINIB

Tablets

APALUTAMIDE

Tablets

APIXABAN

Tablets

APREMILAST

Tablets

ARFORMOTEROL

Inhalation Solution

ATOGEPAANT

Tablets

ATORVASTATIN

Tablets

AZACITIDINE

Injection

B

BARICITINIB

Tablets

BEMPEDOIC ACID

Tablets

BEMPEDOIC ACID+EZETIMIBE

Tablets

BENDAMUSTINE

RTD Injection

BENDAMUSTINE

Injection

BORTEZOMIB

Lyo Injection

BRIMONIDINE

Ophthalmic Solution

C

CABAZITAXEL

Injection

CABOZANTINIB

Tablets

CALCITONIN

Liquid Injection

CAPECITABINE

Tablets

CARBIDOPA + LEVODOPA

ER Capsules

CARBOPROST

PFS Injection

CARFILZOMIB

Injection

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH

INDICATION/ THERAPY
/DISEASE AREADOSSIER STATUS[#]

250 and 500 mg

Oncology

Commercial

100 mg

Oncology

Under Development

60 mg

Oncology

Filed

2.5 and 5 mg

Cardiovascular

Commercial

10, 20 and 30 mg

Psoriasis

Filed

15 mcg/2 ml

Respiratory

Filed

10, 30 and 60 mg

Migraine

Filed

10, 20, 40 and 80 mg

Cardiovascular

Commercial

100 and 150 mg

Oncology

Commercial

1, 2 and 4 mg

Rheumatoid arthritis

Under Development

180 mg

Cardiovascular

Filed

180 mg

Cardiovascular

Filed

180 mg

Oncology

Commercial

25, 100 mg/vial

Oncology

Commercial

3.5 mg

Oncology

Commercial

0.03%

Ophthalmology

Filed

40 mg/ml (1.5 ml)

Oncology

Commercial

20, 40 and 60 mg

Oncology

Under Development

200 IU/ml

Paget's disease

Filed

150 and 500 mg

Oncology

Commercial

36.3mg+145mg,
23.8mg+95mg,
48.8mg+195mg and
61.3mg+245mg

Central Nervous System

Filed

250 mcg/ml

Women's health

Commercial

10, 30 and 60 mg

Oncology

Filed

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

CARMUSTINE	Injection
CELECOXIB	Oral Solution
CINACALCET	Tablets
CIPROFLOXACIN + DEXAMETHASONE	Ear Drops
COLCHICINE	Tablets
CYCLOPHOSPHAMIDE	RTD Injection

D

DABIGATRAN ETEXILATE	Capsules
DAPAGLIFLOZIN	Tablets
DAPTOMYCIN	Injection
DASATINIB MONOHYDRATE	Tablets
DECITABINE	Injection
DESMOPRESSIN	Injection
DEXLANSOPRAZOLE	DR Capsules
DIFLUPREDNATE	Eye Drops
DIMETHYL FUMARATE	Capsules
DOLUTEGRAVIR+LAMIVUDINE	Tablets
DOLUTEGRAVIR+RILPIVIRINE	Tablets

E

EDARAVONE	Injection
EDOABAN	Tablets
ELIGLUSTAT	Capsules
ELTROMBOPAG	Tablets
EMPAGLIFLOZIN	Tablets
EMPAGLIFLOZIN + LINAGLIPTIN	Tablets

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH

INDICATION/ THERAPY
/DISEASE AREADOSSIER STATUS[#]

100 mg

Oncology

Filed

25 mg/1 ml

Pain Management

Commercial

30, 60 and 90 mg

Endocrinology

Commercial

0.3% + 0.1% 7.5 ml

Otolaryngology (ENT)

Filed

0.6 mg

Central Nervous System

Commercial

0.5, 1 and 2 gm

Oncology

Commercial

75, 110 and 150 mg

Cardiovascular

Commercial

5 and 10 mg

Anti-Diabetic

Filed

350 and 500 mg

Anti-Infective

Commercial

20, 50, 70, 80, 100
and 140 mg

Oncology

Filed

50 mg/vial

Oncology

Commercial

4 mcg/ml

Endocrinology/Urology

Commercial

30 and 60 mg

Gastroenterology

Under Development

0.05%

Ophthalmology

Commercial

120 and 240 mg

Multiple sclerosis

Commercial

50 + 300 mg

HIV

Under Development

50 + 25 mg

HIV

Under Development

60 mg/100 ml

Central Nervous System

Filed

15, 30 and 60 mg

Cardiovascular

Filed

84 mg

Type 1 Gaucher disease

Filed

12.5, 25, 50 and 75 mg

Anemia

Filed

10 and 25 mg

Anti-Diabetic

Filed

10 + 5 mg and 25 + 5 mg

Anti-Diabetic

Filed

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

ENZALUTAMIDE

Tablets

ENZALUTAMIDE

Soft gel Capsules

EPHEDRINE

Injection

EPINEPHRINE

Injection

ESOMEPRAZOLE

DR Capsules

EVEROLIMUS

Tablets

F

FERRIC CARBOXY MALTOSE

Injection

FIDAXOMICIN

Tablets

FINGOLIMOD

Capsules

FONDAPARINUX SODIUM

PFS Injection

FORMOTEROL FUMARATE

Inhalation Solution

FOSAPREPITANT

Injection

FULVESTRANT RT

PFS Injection

H

HYDROCORTISONE SODIUM SUCCINATE

Injection

I

IMATINIB

Capsules

IMATINIB

Tablets

ISOTRETINOIN

Capsules

K

KETOROLAC

Injection

KETOROLAC

Tablets

L

LACOSAMIDE

Injection

LANSOPRAZOLE

OD Tablets

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH

INDICATION/ THERAPY
/DISEASE AREADOSSIER STATUS[#]

40 and 80 mg

Oncology

Filed

40 mg

Oncology

Filed

50 mg/ml

Anti-Allergic

Commercial

10 mg/10 ml
and 30 mg/30 ml

Anti-Allergic

Filed

20 and 40 mg

Gastroenterology

Commercial

2.5, 5, 7.5 and 10 mg

Oncology

Commercial

50 mg/ml

Anemia

Filed

200 mg

Anti-Infective

Under Development

0.5 mg

Multiple sclerosis

Commercial

"2.5 mg/0.5 ml,
5 mg/0.4 ml, 7.5 mg/0.6 ml
and 10 mg/0.8 ml"

Cardiovascular

Commercial

20 mcg/2 ml

Respiratory

Filed

150 mg

Oncology (Supportive Care)

Commercial

250 mg/5 ml

Oncology

Filed

100 mg

Anti-Inflammatory

Filed

100 and 400 mg

Oncology

Commercial

100 and 400 mg

Oncology

Commercial

10, 20, 30 and 40 mg

Acne

Commercial

30 mg/ ml

Pain Management

Commercial

10 mg

Pain Management

Commercial

200 mg/20 ml

Central Nervous System

Commercial

15 and 30 mg

Gastroenterology

Commercial

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

LATANOPROSTENE BUNOD

Ophthalmic Solution

LENALIDOMIDE

Capsules

LENVATINIB

Capsules

LETERMOVIR

Tablets

LINAGLIPTIN

Tablets

LINAGLIPTIN+METFORMIN

Tablets

LIRAGLUTIDE

Injection Pen

LIRAGLUTIDE

Injection Pen

LOXOPROFEN

Powder for Oral Solution - Sachet

LOXOPROFEN

Tablets

LUMATEPERONE

Tablets

M

MIDOSTAURIN

Soft gel Capsules

N

NALOXONE

Injection

NANO PACLITAXEL

Injection

NAPROXEN

Tablets

NELARABINE

Injection

NEOSTIGMINE

Injection

NICOTINE

Mini Lozenges

NILOTINIB

Capsules

NINTEDANIB

Soft gel Capsules

O

OLAPARIB

Tablets

P

PALBOCICLIB

Tablets

PALBOCICLIB

Capsules

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH

INDICATION/ THERAPY
/DISEASE AREADOSSIER STATUS[#]

0.024%

Ophthalmology

Filed

2.5, 5, 10, 15, 20 and 25 mg

Oncology

Commercial

4 and 10 mg

Oncology

Filed

240 and 480 mg

Infectious Disease (CMV)

Under Development

5 mg

Anti-Diabetic

Filed

2.5 mg/500 mg, 2.5 mg/
850 mg and 2.5 mg/1 g

Anti-Diabetic

Filed

6 mg/ml (3 ml)

Obesity

Filed

6 mg/ml (3 ml)

Anti-Diabetic

Filed

60 mg

Pain Management

Filed

60 mg

Pain Management

Filed

10.5, 21 and 42 mg

Central Nervous System

Filed

25 mg

Oncology

Filed

2 mg/2 ml

Central Nervous System

Commercial

100 mg

Oncology

Filed

275 and 550 mg

Pain Management

Commercial

250 mg/50 ml

Oncology

Commercial

0.5 mg/1 ml, 1 mg/ ml
and 3 mg/3 ml

Myasthenia gravis

Commercial

2 and 4 mg

Smoking Cessation

Commercial

50, 150 and 200 mg

Oncology

Commercial

100 and 150 mg

Oncology

Filed

100 and 150 mg

Oncology

Under Development

75, 100 and 125 mg

Oncology

Filed

75, 100 and 125 mg

Oncology

Filed

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

PALONOSETRON	Injection
PAZOPANIB	Tablets
PEMETREXED	Injection
PLERIXAFOR	Injection
POMALIDOMIDE	Capsules
POSACONAZOLE	DR Tablets
PRALATREXATE	Injection
PREDNISOLONE ACETATE	Ophthalmic Suspension

R

REGADENOSON	Injection
REGORAFENIB	Tablets
RELUGOLIX	Tablets
RIFAXIMIN	Tablets
RIVAROXABAN	Tablets

S

SACUBITRIL+VALSARTAN	Tablets
SAPROPTERIN	Powder for Oral Solution
SAPROPTERIN	Tablets
SELATOGREL	Injection
SEMAGLUTIDE	Injection
SEMAGLUTIDE	Tablets
SEMAGLUTIDE	Tablets
SEMAGLUTIDE	Injection Pen
SEVELAMER	Powder for Oral Suspension

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH	INDICATION/ THERAPY /DISEASE AREA	DOSSIER STATUS [#]
0.075 mg/5 ml and 0.25 mg/ 5 ml	Anti-Emetic	Commercial
200 and 400 mg	Oncology	Commercial
100 mg/vial, 500 mg/vial and 1 g/vial	Oncology	Commercial
24 mg/1.2 ml	Oncology (Supportive Care)	Commercial
1, 2, 3 and 4 mg	Oncology	Commercial
100 mg	Anti-Infective	Commercial
20 mg/ml and 40 mg/2 ml	Oncology	Filed
1%	Ophthalmology	Under Development
0.4 mg/5 ml	Cardiovascular	Commercial
40 mg	Oncology	Filed
120 mg	Oncology	Filed
550 mg	Anti-Infective	Under Development
2.5, 10, 15 and 20 mg	Cardiovascular	Commercial
24/26, 49/51 and 97/103 mg	Cardiovascular	Filed
100 mg	Phenylketonuria	Commercial
100 mg	Phenylketonuria	Commercial
16 mg/0.5 ml	Cardiovascular	Under Development
2 mg/1.5 ml, 2 mg/3 ml, 4 mg/3 ml and 8 mg/3 ml	Anti-Diabetic	Commercial
3, 7 and 14 mg	Anti-Diabetic	Filed
1.5, 4 and 9 mg	Anti-Diabetic Obesity	Under Development
1 mg/1.5 ml, 2 mg/1.5 ml, 4 mg/3 ml, 6.8 mg/3 ml and 9.6 mg/3 ml	Obesity	Under Development
800 mg and 2.4 gm	Urology	Commercial

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

SEVELAMER	Tablets
SIPONIMOD	Tablets
SIROLIMUS	Tablets
SITAGLIPTIN	Tablets
SITAGLIPTIN +METFORMIN	Tablets
SODIUM NITROPRUSSIDE	Injection
SORAFENIB	Tablets
SUGAMMADEX	Injection
SUNITINIB	Capsules

T

TAFAMIDIS MEGLUMINE	Soft gel Capsules
TAPINAROF	Cream
TELMISARTAN + AMLODIPINE	Tablets
TERIPARATIDE	Injection
TICAGRELOR	Tablets
TIMOLOL MALEATE	Ophthalmic Gel forming Solution
TOPIRAMATE	XR Capsules
TREPROSTINIL	Injection
TRIAMCINOLONE ACETONIDE	Injection
TRILACICLIB DIHYDROCHLORIDE	Injection

U

UPADACITINIB	ER Tablets
UPADACITINIB	Oral Solution

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH

INDICATION/ THERAPY
/DISEASE AREADOSSIER STATUS[#]

800 mg	Urology	Commercial
0.25, 1 and 2 mg	Multiple sclerosis	Filed
1, 2 mg	Immunosuppressant	Commercial
25, 50 and 100 mg	Anti-Diabetic	Commercial
50 + 500 mg and 50 + 1000 mg	Anti-Diabetic	Commercial
50 mg/2 ml	Cardiovascular	Filed
200 mg	Oncology	Commercial
100 mg/ml (2 ml and 5 ml)	Central Nervous System	Commercial
12.5, 25, 37.5 and 50 mg	Oncology	Commercial
21 mg	Cardiovascular	Filed
1%	Plaque psoriasis	Under Development
40 + 5 mg, 40 + 10 mg, 80 + 5 mg and 80 + 10 mg	Cardiovascular	Filed
0.25 mg/ml (2.4 ml)	Anti-Osteoporosis	Filed
60 and 90 mg	Cardiovascular	Commercial
0.25% and 0.50%	Ophthalmology	Filed
25, 50, 100 and 200 mg	Central Nervous System	Commercial
1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml)	Cardiovascular	Commercial
50 mg/5 ml, 40 mg/1ml, 200 mg/5 ml and 400 mg/10 ml	Anti-Inflammatory	Commercial
300 mg	Oncology	Filed
15, 30 and 45 mg	Rheumatoid arthritis	Under Development
1 mg/ml	Rheumatoid arthritis	Under Development

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.

PRODUCT NAME*

DOSAGE FORM

V

VALGANCICLOVIR

Tablets

VARENICLINE

Tablets

VASOPRESSIN

Injection

VIGABATRIN

Powder for Oral Solution - Sachet

VIGABATRIN

Tablets

VITAMIN K1

Injection

VOCLOSPORIN

Soft Gel Capsules

VONOPRAZAN

Tablets

VORICONAZOLE

Tablets

Z

ZAFIRLUKAST

Tablets

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

STRENGTH**INDICATION/ THERAPY
/DISEASE AREA****DOSSIER STATUS[#]**

450 mg

Anti-Viral

Commercial

0.5 and 1 mg

Smoking cessation

Commercial

20 IU/ml

Endocrinology

Commercial

500 mg

Central Nervous System

Commercial

500 mg

Central Nervous System

Commercial

10 mg/ml

Hematology

Filed

7.9 mg

Nephrology

Filed

10 and 20 mg

Gastroenterology

Filed

50 and 200 mg

Anti-Infective

Commercial

10 and 20 mg

Respiratory

Commercial

[#] The dossier status information presented in this brochure is based on the approval status provided by Dr. Reddy's Laboratories. The status is subject to change based on regulatory submissions, approvals, business decisions, or market conditions.



api.drreddys.com | api@drreddys.com

Published date: 2nd July, 2026

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.